NCT05821478 - Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 27, 2028

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy

a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin

DRUG

Lymecyclin and corresponding placebos of the experimental arm

12-week course of oral lymecycline.

Trial Locations (4)

Unknown

NOT_YET_RECRUITING

Hôpital de la Timone, Marseille

RECRUITING

Centre Médical de l'Institut Pasteur, Paris

ACTIVE_NOT_RECRUITING

Hopital St Joseph, Paris

NOT_YET_RECRUITING

CHU de Rouen, Rouen